Every material Form 8-K Estrella Immunopharma, Inc. has filed with the SEC since August 21, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Estrella Immunopharma appointed Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board effective October 25, 2026, replacing Cheng Liu, Ph.D., who became Chief Scientific Officer while remaining President and a director. The filing also sets Pussinen's pay package, including a 1,000,000-share option grant and base salary increases tied to future financing, and says the Board adopted a plan to propose a change to its director class structure for stockholder vote in 2027.
Cynthia Pussinen, age 57, appointed CEO, Class I director and Board Chairperson effective October 25, 2026
Pussinen's base salary is $250,000, rising to $400,000, $450,000 and $525,000 as cumulative qualifying funding after October 25, 2026 exceeds $35.0 million, $55.0 million and $75.0 million
Option to purchase 1,000,000 shares granted on the second business day after the filing, with 25% vesting on October 25, 2027
Proposed amendment to Article V, Section A to be submitted to stockholders at the 2027 annual meeting
Estrella Immunopharma received a Nasdaq notice on September 1, 2026, stating its market value of listed securities fell below the $35 million minimum for 30 consecutive business days. The company has until March 1, 2027 to regain compliance, and the stock continues to trade on Nasdaq for now, but failure to comply could lead to delisting proceedings.
Nasdaq notice dated September 1, 2026 cites market value of listed securities below $35,000,000 for 30 consecutive business days, July 21 through August 31, 2026
Company does not meet Nasdaq's alternative standards for stockholders' equity of at least $2,500,000 or net income of at least $500,000
Compliance deadline is March 1, 2027; regaining compliance requires closing at $35,000,000 or more for at least ten consecutive business days
Common stock continues to trade on The Nasdaq Capital Market under the symbol ESLA
Estrella Immunopharma received a Nasdaq notice on August 17, 2026, stating its common stock closed below $1.00 for 30 consecutive business days, so it no longer meets the minimum bid price requirement. The notice has no immediate effect on trading, and the company has until February 16, 2027 to regain compliance, which could involve a reverse stock split.
Nasdaq letter dated August 17, 2026 cites closing bid price below $1.00 from July 6, 2026 through August 14, 2026
Compliance period runs 180 calendar days, until February 16, 2027
Common stock continues to trade on The Nasdaq Capital Market under the symbol ESLA
If not compliant by the deadline, the company may be eligible for a second 180-day period, or face delisting notice and an appeal
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Estrella Immunopharma, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →